Rani Therapeutics Holdings, Inc.

NasdaqGM RANI

Rani Therapeutics Holdings, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 2.02 M

Rani Therapeutics Holdings, Inc. Gross Profit is USD 2.02 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 213.17% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Rani Therapeutics Holdings, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.78 M.
Rani Therapeutics Holdings, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 2.81 M.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGM: RANI

Rani Therapeutics Holdings, Inc.

CEO	Mr. Talat Imran
IPO Date	July 30, 2021
Location	United States
Headquarters	2051 Ringwood Avenue
Employees	140
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Key trends

Past 5 years